Supply chains and AI take precedence at European clinical trial meeting
As global supply chains come under increasing strain and AI disrupts how clinical trials are conducted, experts will congregate to…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
Radiopharmaceutical deals drive sector growth despite supply crisis
A reinvigorated interest in radiopharmaceuticals has brought nuclear medicine to the foreground with deals over 2024 further exemplifying this trend.…
-
NVIDIA champions Innophore partnership to model drug dynamics with AI
NVIDIA and Innophore’s collaborative artificial intelligence (AI)-driven, drug safety screening platform CavitOmiX is set to launch in late January 2025,…
-
JP Morgan 2025: Radiopharmaceuticals M&A fuels Telix’s busy year
Following a year thick with acquisitions across the radiopharmaceutical supply chain, Telix Pharmaceuticals has announced a 55% year-on-year revenue increase…
-
JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead
AstraZeneca says a strong 2024 and stacked pipeline spells potential for further growth in 2025 as the company aims to…
-
JP Morgan 2025: Novartis streamlines its portfolio to drive future growth
Positioning itself as a pure-play innovative medicines company, Novartis is bullish about the growth towards 2030 by placing an emphasis…
-
JP Morgan 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance
Moderna lost more than 20% of its value on the stock market as the company delivered slashed revenue guidance for…
-
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues…
-
Eisbach Bio positions HRD-targeting therapy to supplant PARP inhibitors
Eisbach Bio plans to use a $4.75m grant to advance EIS-12656, a small molecule ALC1 inhibitor to disrupt the genome…
-
How Pfizer management outplayed activist investor Starboard
Amidst dwindling share prices and widespread criticism, Pfizer CEO Albert Bourla appears to have withstood an attempted ousting by activist…